SCI时时刷

search
+
Noncoding RNA-encoded peptides in cancer: biological functions, posttranslational modifications and therapeutic potential
Noncoding RNA-encoded peptides in cancer: biological functions, posttranslational modifications and therapeutic potential
In the present era, noncoding RNAs (ncRNAs) have become a subject of considerable scientific interest, with peptides encod...
Cancer vaccines: current status and future directions
Cancer vaccines: current status and future directions
Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune ...
IL-15: from discovery to FDA approval
IL-15: from discovery to FDA approval
FDA. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. 2024Waldmann ...
Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells
Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells
Natural products have long been a viable source of therapeutic agents, providing unique structures and mechanisms that may...
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, ...
Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer
Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive and heterogeneous subtype, representing 15% of lung cancer cases. Although ...
N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential
N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential
N7-methylguanosine (m7G) is an important RNA modification involved in epigenetic regulation that is commonly observed in b...
Helicobacter pylori and gastric cancer: mechanisms and new perspectives
Helicobacter pylori and gastric cancer: mechanisms and new perspectives
Gastric cancer remains a significant global health challenge, with Helicobacter pylori (H. pylori) recognized as a major e...
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment option...
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in ...
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults
Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults su...
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consis...
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021
Female-specific cancers, particularly breast, cervical, ovarian, and uterine cancers, account for nearly 40% of all cancer...
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint
D-ribose-5-phosphate inactivates YAP and functions as a metabolic checkpoint
Targeting glucose uptake by glucose transporter (GLUT) inhibitors is a therapeutic opportunity, but efforts on GLUT inhibi...
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lympho...
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patie...
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and PD-1 is believed to enhance cancer immunother...
Current and future immunotherapy for breast cancer
Current and future immunotherapy for breast cancer
Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint in...
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its...
myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment
myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment
Liver metastasis from colorectal cancer (CRC) is a major clinical challenge that severely affects patient survival. myofib...
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study
Yan Bian, Ye Gao, Han Lin and Chang Sun contributed equally to this work.Department of Gastroenterology, Changhai Hospital...
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Accumulation of malignant plasma cells in the bone marrow causes lytic bone lesions in 80% of multiple myeloma patients. F...
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study
Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep mole...
Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system
Engineering a controllable and reversible switch for CAR-based cellular immunotherapies via a genetic code expansion system
As one of the most promising adoptive cell therapies, CAR-T cell therapy has achieved notable clinical effects in patients...
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021
Cancer is the second most common cause of death globally. Therefore, it is imperative to investigate cancer incidence, mor...
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer
Immunotherapy resistance in bladder cancer (BLCA) is associated with elevated levels of sialic acid–binding immunogl...
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy
CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual rol...
Personalized nanovaccines for treating solid cancer metastases
Personalized nanovaccines for treating solid cancer metastases
Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical respons...
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
There is an unmet clinical need to enhance the response rate and safety of anti-PD-1/PD-L1-based cancer immunotherapy (IO)...
Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma
Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma
Lung adenocarcinoma (LUAD) is one of the leading causes of cancer-related deaths worldwide, with a 5-year survival rate of...
阅读更多
format_indent_increase